The level of estrogen receptor (ER), progesterone receptor (PR) and HER2 expression is predictive for prognosis and/or treatment response in breast cancer patients. However, differences in fixation and IHC and subjective interpretation can substantially affect the accuracy and reproducibility of the results. The commercially available TargetPrint test measures the mRNA expression level of ER, PR and HER2 and
provides high quality second opinion for local IHC/FISH assessment.
This study compares results from the microarray-based TargetPrint with IHC and FISH (for HER2 IHC2+) generated by local standard procedures.
Microarray based readout of ER, PR and HER2 status using
TargetPrint is highly comparable to local IHC and FISH analysis
in 749 analyzed samples in various hospitals worldwide. The
results indicate mRNA expression read out for ER, PR and HER2
by TargetPrint provides high quality second opinion for local IHC/
FISH assessment.
